secwatch.observer — SEC 8-K summary
======================================

Issuer:     PharmaCyte Biotech, Inc. (PMCB)
CIK:        0001157075
Form:       8-K
Filed at:   2022-12-30T23:59:59+00:00
Accession:  0001683168-22-008705
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

PharmaCyte Biotech shareholders approve reverse stock split, increase authorized shares to 133M
--------------------------------------------------------------------------------

- Reverse stock split at ratio of 1:5 to 1:20 approved with 11,385,563 votes for, 2,067,045 against.
- Authorized common shares increased from 33,333,334 to 133,333,334 approved with 11,020,851 for.
- 2022 Equity Incentive Plan approved with 6,532,612 for, 1,162,890 against.
- All five director nominees elected; Armanino LLP ratified as auditor for FY ending April 30, 2023.
- Advisory vote on executive compensation passed; frequency of every year selected by 7,493,683 votes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1157075/000168316822008705/0001683168-22-008705-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1157075/000168316822008705/pharmacyte_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-22-008705

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer